Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelly G Adel

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The American Journal of Managed Care|April 15, 2021
Current treatment landscape and emerging therapies for metastatic triple-negative breast cancerNelly G Adel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Leukemia Research|June 18, 2013
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic deathJessica K Altman, Alfred Rademaker, Elizabeth Cull, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The American Journal of Managed Care|April 15, 2021
Current treatment landscape and emerging therapies for metastatic triple-negative breast cancerNelly G Adel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Leukemia Research|June 18, 2013
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic deathJessica K Altman, Alfred Rademaker, Elizabeth Cull, et al.
Pageof 1